США - англійська - NLM (National Library of Medicine)

sandoz inc. - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c) - clindamycin 10 mg in 1 g - clindamycin and benzoyl peroxide gel, 1%/5% is indicated for the topical treatment of acne vulgaris. clindamycin and benzoyl peroxide gel, 1%/5% is contraindicated in those individuals who have shown hypersensitivity to any of its components or to lincomycin. it is also contraindicated in those having a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

США - англійська - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - sulindac (unii: 184sns8vuh) (sulindac - unii:184sns8vuh) - sulindac 200 mg - carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). sulindac tablets, usp are indicated for acute or long-term use in the relief of signs and symptoms of the following: - osteoarthritis osteoarthritis - rheumatoid arthritis** rheumatoid arthritis** - ankylosing spondylitis ankylosing spondylitis - acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis) acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis) - acute gouty arthritis acute gouty arthritis **the safety and effectiveness of sulindac have not been established in rheumatoid arthritis patients who are designated in the american rheumatism association classification as functional class iv (incapacitated, largely or wholly bedridden, or confined to wheelchair; little or no self-care). sulindac tablets are contraindicated in patients with known hypersensitivity to sulindac or the excipients (see description ). sulindac tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/anaphylactoid reactions to nsaids have been reported in such patients (see warnings – anaphylactic/anaphylactoid reactions , and precautions – preexisting asthma ). • in the setting of coronary artery bypass graft (cabg) surgery (see warnings)

США - англійська - NLM (National Library of Medicine)

alvogen inc. - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c) - clindamycin phosphate 150 mg in 1 ml - clindamycin injection, usp is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin injection, usp is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of antibiotic-associated pseudomembranous colitis, as described in the boxed warning , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. indicated surgical procedures should be performed in conjunction with antibiotic therapy. clindamycin injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the d

США - англійська - NLM (National Library of Medicine)

sagent pharmaceuticals - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c) - clindamycin 150 mg in 1 ml - clindamycin injection, usp is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin injection, usp is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of antibiotic-associated pseudomembranous colitis, as described in the boxed warning , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. indicated surgical procedures should be performed in conjunction with antibiotic therapy. clindamycin injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, streptococcus pneumoniae, other streptococci (except e. faecalis ), and staphylococcus aureus. skin and skin structure infections caused by streptococcus pyogenes, staphylococcus aureus , and anaerobes. gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. septicemia caused by staphylococcus aureus , streptococci (except enterococcus faecalis ), and susceptible anaerobes. bone and joint infections including acute hematogenous osteomyelitis caused by staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. to reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin injection, usp and other antibacterial drugs, clindamycin injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. this drug is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

США - англійська - NLM (National Library of Medicine)

alvogen inc. - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c) - clindamycin phosphate 150 mg in 1 ml - clindamycin injection, usp is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin injection, usp is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of antibiotic-associated pseudomembranous colitis, as described in the boxed warning , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. indicated surgical procedures should be performed in conjunction with antibiotic therapy. clindamycin injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the d

США - англійська - NLM (National Library of Medicine)

state of florida doh central pharmacy - sulindac (unii: 184sns8vuh) (sulindac - unii:184sns8vuh) - sulindac 200 mg - carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). sulindac tablets are indicated for acute long-term use in the relief of signs and symptoms of the following: - osteoarthritis osteoarthritis - rheumatoid arthritis* rheumatoid arthritis* - ankylosing spondylitis ankylosing spondylitis - acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis) acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis) - acute gouty arthritis acute gouty arthritis sulindac is contraindicated in patients with known hypersensitivity to sulindac or the excipients (see description ). sulindac should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/anaphylactoid reactions to ns

США - англійська - NLM (National Library of Medicine)

major pharmaceuticals - sulindac (unii: 184sns8vuh) (sulindac - unii:184sns8vuh) - sulindac 150 mg - carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). sulindac is indicated for acute or long-term use in the relief of signs and symptoms of the following: 1. osteoarthritis 2. rheumatoid arthritis** 3. ankylosing spondylitis 4. acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis) 5. acute gouty arthritis sulindac is contraindicated in patients with known hypersensitivity to sulindac or the excipients (see description ). sulindac should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/anaphylactoid reactions to nsaids have been reported in such patients (see warnings – anaphylactic/anaphylactoid reactions, and precautions – preexisting asthma ). sulindac is contraindicated

США - англійська - NLM (National Library of Medicine)

actavis pharma, inc. - sulindac (unii: 184sns8vuh) (sulindac - unii:184sns8vuh) - sulindac 150 mg - carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). sulindac tablets, usp are indicated for acute or long-term use in the relief of signs and symptoms of the following: - osteoarthritis osteoarthritis - rheumatoid arthritis** rheumatoid arthritis** - ankylosing spondylitis ankylosing spondylitis - acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis) acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis) - acute gouty arthritis acute gouty arthritis **the safety and effectiveness of sulindac have not been established in rheumatoid arthritis patients who are designated in the american rheumatism association classification as functional class iv (incapacitated, largely or wholly bedridden, or confined to wheelchair; little or no self-care). sulindac tablets are co

США - англійська - NLM (National Library of Medicine)

mylan institutional inc. - sulindac (unii: 184sns8vuh) (sulindac - unii:184sns8vuh) - sulindac 200 mg - carefully consider the potential benefits and risks of sulindac tablets, usp and other treatment options before deciding to use sulindac tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). sulindac tablets are indicated for acute or long-term use in the relief of signs and symptoms of the following: - osteoarthritis - rheumatoid arthritis * - ankylosing spondylitis - acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis) - acute gouty arthritis * the safety and effectiveness of sulindac have not been established in rheumatoid arthritis patients who are designated in the american rheumatism association classification as functional class iv (incapacitated, largely or wholly bedridden, or confined to wheelchair; little or no self-care). sulindac tablets are contraindicated in patients with known hypersensitivity to sulindac or the excipients (see

США - англійська - NLM (National Library of Medicine)

h.j. harkins company, inc. - sulindac (unii: 184sns8vuh) (sulindac - unii:184sns8vuh) - sulindac 200 mg - carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). sulindac tablets are indicated for acute long-term use in the relief of signs and symptoms of the following: - osteoarthritis osteoarthritis - rheumatoid arthritis* rheumatoid arthritis* - ankylosing spondylitis ankylosing spondylitis - acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis) acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis) - acute gouty arthritis acute gouty arthritis sulindac tablets are contraindicated in patients with known hypersensitivity to sulindac or the excipients (see description ). sulindac tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/anaphylactoi